Zabadinostat
Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity[1][2].
Product Specifications
CAS Number
934828-12-3
Product Name Alternative
CXD101
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zabadinostat.html
Purity
99.83
Solubility
DMSO : ≥ 31 mg/mL
Smiles
O=C(NC1=C(N)C=CC=C1)C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2
Molecular Formula
C24H29N5O
Molecular Weight
403.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Eyre TA, et al. Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors? Oncotarget. 2018 Dec 18;9 (99) :37280-37281.|[2]Eyre TA, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 2019 Jan 1;125 (1) :99-108.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HDAC1; HDAC2; HDAC3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942646-100 1x 100 µL
CD73 (Immuno-Oncology Target) (NT5E/2646), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
